Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio su JNJ-80948543, un anticorpo di reindirizzamento delle cellule T, nel linfoma non Hodgkin (NHL) e nella leucemia linfocitica cronica (LLC)

25 settembre 2026 aggiornato da: Janssen Research & Development, LLC

Uno studio di fase 1, primo sull'uomo di JNJ-80948543, un anticorpo di reindirizzamento delle cellule T, in partecipanti con NHL e CLL

The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D[s]), optimal dosing schedule(s) and route(s) of administration of JNJ-80948543 in Part A (Dose Escalation) and to further characterize the safety of JNJ-80948543 at the putative RP2D(s) in Part B (Cohort Expansion).

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

167

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Macquarie University, Australia, 2109
        • Macquarie University Hospital
      • Melbourne, Australia, 3004
        • The Alfred Hospital
      • Nedlands, Australia, 6009
        • Linear Clinical Research Ltd
      • Randwick, Australia, 2031
        • Scientia Clinical Research
      • Chongqing, Cina, 400044
        • Chongqing University Cancer Hospital
      • Guangzhou, Cina, 510060
        • Sun Yat Sen University Cancer Center
      • Tianjin, Cina, 300060
        • Tianjin cancer hospital
      • Wuhan, Cina, 430030
        • Union Hospital Tongji Medical College of Huazhong University of Science and Technology
      • Copenhagen, Danimarca, 2100
        • Rigshospitalet
      • Odense, Danimarca, 5000
        • Odense University Hospital
      • Lille, Francia, 59037
        • CHRU de Lille Hopital Claude Huriez
      • Paris, Francia, 75005
        • Institut Curie
      • Strasbourg, Francia, 67033
        • Institut de Cancerologie Strasbourg Europe ICANS
      • Toulouse, Francia, 31059
        • Institut Universitaire du cancer de Toulouse-Oncopole
      • Kashiwa, Giappone, 277 8577
        • National Cancer Center Hospital East
      • Nagoya, Giappone, 464 8681
        • Aichi Cancer Center
      • Tokyo, Giappone, 135 8550
        • The Cancer Institute Hospital of JFCR
      • Haifa, Israele, 34362
        • Carmel Medical Center
      • Jerusalem, Israele, 9112001
        • Hadassah Medical Center
      • Tel Aviv, Israele, 64239
        • Tel Aviv Sourasky Medical Center
      • Gdansk, Polonia, 80 214
        • Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz
      • Skorzewo, Polonia, 60-185
        • Aidport Sp z o o
    • California
      • Duarte, California, Stati Uniti, 91010
        • City of Hope
    • New York
      • New York, New York, Stati Uniti, 10065
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, Stati Uniti, 10029
        • Icahn School of Medicine at Mount Sinai
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37203
        • Sarah Cannon Research Institute
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • The University of Texas MD Anderson Cancer Center
      • San Antonio, Texas, Stati Uniti, 78229
        • Texas Transplant Institute
    • Washington
      • Seattle, Washington, Stati Uniti, 98109
        • Seattle Cancer Care Alliance

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Histologic documentation of disease: B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) requiring therapy.

All participants must have relapsed or refractory disease with no other approved therapies available that would be more appropriate in the investigator's judgment.

B-cell NHL as defined per the 2016 world health organization (WHO) classification. In addition, the following disease-specific criteria outlined below must be met:

If diffuse large B-cell lymphoma (DLBCL) or other high-Grade B-cell lymphoma: Received, or not eligible for high-dose chemotherapy and autologous stem cell transplantation with curative intent or deemed not eligible or fit for an alternative 2nd line therapy. Participants may be eligible if relapsing after chimeric antigen receptors (CAR-T) cell treatment or while waiting for a CAR-T cell treatment.

If transformed lymphoma from low Grade B-cell malignancies: Received or not a candidate for an approved first-line regimen for DLBCL and received or not eligible for high-dose chemotherapy and autologous stem cell transplantation with curative intent.

If follicular lymphoma (FL) (all grades): Previously treated with a minimum of 2 prior lines of systemic therapy, with at least one prior line containing an anti-CD20 antibody.

If mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) (including nodal, extranodal/MALT, and splenic MZL subtypes): Previously treated with at least 2 lines of systemic therapy. H.pylori-positive gastric MALT lymphoma must have failed prior H. pylori eradication therapy as one of their prior lines .

Waldenstrom macroglobulinemia (WM): Previously treated with at least 1 line of systemic therapy.

small lymphocytic lymphoma/chronic lymphocytic leukemia (CLL/SLL): Relapsed or refractory with at least 2 prior lines of therapy, including a Bruton tyrosine kinase inhibitor (BTK) inhibitor or a BCL2 inhibitor, if eligible. In addition for part B Participants must have measurable disease as defined by the appropriate disease response criteria

  • Eastern Cooperative Oncology Group (ECOG) performance status Grade of 0 or 1
  • Cardiac parameters within the following range: corrected QT interval (QTc intervals corrected using Fridericia's formula [QTcF]) less than or equal to (<=) 480 milliseconds based on the average of triplicate assessments performed no more than 5 (plus minus [+-] 3) minutes apart
  • A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (beta- human chorionic gonadotropin) at screening and must agree to further serum or urine pregnancy tests prior to the first dose, during the study and until 3 months after the last dose of study treatment
  • A female participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 3 months after the last dose of study treatment

Exclusion Criteria:

  • Known active central nervous system (CNS) involvement; Lymphoma with CNS involvement may be allowed in pharmacokinetic/ pharmacodynamic (PK/PD) and expansion cohorts if approved by the study evaluation team (SET)
  • Prior solid-organ transplantation
  • Autoimmune or inflammatory disease requiring systemic steroids or other immunosuppressive agents (example, methotrexate or tacrolimus) within 1 year prior to first dose of study drug
  • Toxicity from prior anticancer therapy has not resolved to baseline levels or to Grade <= 1 (except alopecia, vitiligo, peripheral neuropathy, or endocrinopathies that are stable on hormone replacement, which may be Grade 2)
  • Clinically significant pulmonary compromise, particularly the need for supplemental oxygen use to maintain adequate oxygenation

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Part A: Dose Escalation

Participants will receive JNJ-80948543 either by subcutaneous (SC) or intravenous (IV) administration to determine the putative recommended Phase 2 dose (RP2D) dosing schedule(s) and route(s) of administration based on safety, pharmacokinetic, pharmacodynamic, and preliminary assessment of efficacy across several dose regimens.

JNJ-80948543 will be administered as SC or IV injection.

Sperimentale: Part B: Cohort Expansion

Participants will receive JNJ-80948543 by SC or IV administration.

JNJ-80948543 will be administered as SC or IV injection.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of Participants with Dose-limiting Toxicity (DLT)
Lasso di tempo: Up to 4 Years 3 months

Number of participants with DLT will be reported. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.

Up to 4 Years 3 months
Number of Participants with Adverse Events (AEs)
Lasso di tempo: Up to 4 Years 3 months

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

Up to 4 Years 3 months
Number of Participants with AE by Severity
Lasso di tempo: Up to 4 Years 3 months

Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). Severity scale ranges from Grade 1 (Mild) to Grade 4 (Life-threatening). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded as per American Society for Transplantation and Cellular Therapy (ASTCT).

Up to 4 Years 3 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Serum Concentration of JNJ-80948543
Lasso di tempo: Up to 4 Years 3 months

Serum samples will be analyzed to determine concentrations of JNJ-80948543 using a validated, specific, and sensitive method.

Up to 4 Years 3 months
Number of Participants with Presence of Anti-Drug Antibodies of JNJ-80948543
Lasso di tempo: Up to 4 Years 3 months

Number of participants with presence of anti-drug antibodies of JNJ-80948543 will be assessed.

Up to 4 Years 3 months
Overall Response Rate (ORR)
Lasso di tempo: Up to 4 Years 3 months

ORR is defined as the percentage of participants who have a best response of partial response (PR) or better.

Up to 4 Years 3 months
Complete Response (CR) Rate
Lasso di tempo: Up to 4 Years 3 months

CR rate is defined as the percentage of participants who achieve a best response of CR.

Up to 4 Years 3 months
Rate of VGPR or Better for Participants with Waldenstrom Macroglobulinemia (WM)
Lasso di tempo: Up to 4 Years 3 months

The response criteria planned to be used for participants with WM includes a category of VGPR, which is clinically understood to be better than PR but not as good as CR. For participants with WM, this rate is defined as the proportion of participants who achieve a best response of VGPR or better.

Up to 4 Years 3 months
Time to Response (TTR)
Lasso di tempo: Up to 4 Years 3 months

TTR is defined for participants who achieved PR or CR as the time from the first dose of study drug to first response of PR or CR.

Up to 4 Years 3 months
Duration of Response (DOR)
Lasso di tempo: Up to 4 Years 3 months

DOR is defined for participants who achieved a response of PR or better as the time between the date of initial documentation of first response of PR or better to the date of first documented evidence of progressive disease or death.

Up to 4 Years 3 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

18 agosto 2022

Completamento primario (Effettivo)

31 ottobre 2025

Completamento dello studio (Stimato)

30 luglio 2027

Date di iscrizione allo studio

Primo inviato

15 giugno 2022

Primo inviato che soddisfa i criteri di controllo qualità

15 giugno 2022

Primo Inserito (Effettivo)

21 giugno 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

28 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

25 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • CR109174
  • 2022-000685-18 (Numero EudraCT)
  • 80948543LYM1001 (Altro identificatore: Janssen Research & Development, LLC)
  • 2023-504187-42-00 (Identificatore di registro: EUCT number)
  • 2023 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .